Adicet Bio Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $331.24 million
- Book Value:
- Revenue TTM:
- $30.46 million
- Operating Margin TTM:
- Gross Profit TTM:
- $9.73 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Adicet Bio Inc had its IPO on 2018-01-26 under the ticker symbol ACET.
The company operates in the Healthcare sector and Biotechnology industry. Adicet Bio Inc has a staff strength of 86 employees.
Shares of Adicet Bio Inc opened at $7.62 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $7.29 - $7.67, and closed at $7.43.
This is a -3.63% slip from the previous day's closing price.
A total volume of 3,544,200 shares were traded at the close of the day’s session.
In the last one week, shares of Adicet Bio Inc have slipped by -0.13%.
Adicet Bio Inc's Key Ratios
Adicet Bio Inc has a market cap of $331.24 million, indicating a price to book ratio of 2.3297 and a price to sales ratio of 13.9986.
In the last 12-months Adicet Bio Inc’s revenue was $30.46 million with a gross profit of $9.73 million and an EBITDA of $-55627000. The EBITDA ratio measures Adicet Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Adicet Bio Inc’s operating margin was -188.81% while its return on assets stood at -11.76% with a return of equity of -20.84%.
In Q3, Adicet Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1.1%.
Adicet Bio Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.82. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adicet Bio Inc’s profitability.
Adicet Bio Inc stock is trading at a EV to sales ratio of 15.7292 and a EV to EBITDA ratio of -8.9083. Its price to sales ratio in the trailing 12-months stood at 13.9986.
Adicet Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $354.30 million
- Total Liabilities
- $17.22 million
- Operating Cash Flow
- Capital Expenditure
- $4.81 million
- Dividend Payout Ratio
Adicet Bio Inc ended 2023 with $354.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $354.30 million while shareholder equity stood at $317.66 million.
Adicet Bio Inc ended 2023 with $0 in deferred long-term liabilities, $17.22 million in other current liabilities, 4000.00 in common stock, $-208240000.00 in retained earnings and $19.46 million in goodwill. Its cash balance stood at $282.68 million and cash and short-term investments were $282.68 million. The company’s total short-term debt was $2,409,000 while long-term debt stood at $0.
Adicet Bio Inc’s total current assets stands at $285.74 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $29000.00 compared to accounts payable of $4.57 million and inventory worth $0.
In 2023, Adicet Bio Inc's operating cash flow was $-4811000.00 while its capital expenditure stood at $4.81 million.
Comparatively, Adicet Bio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Adicet Bio Inc stock is currently trading at $7.43 per share. It touched a 52-week high of $21.87 and a 52-week low of $21.87. Analysts tracking the stock have a 12-month average target price of $27.36.
Its 50-day moving average was $8.19 and 200-day moving average was $13.43 The short ratio stood at 8.97 indicating a short percent outstanding of 0%.
Around 482.8% of the company’s stock are held by insiders while 10117.9% are held by institutions.
Frequently Asked Questions About Adicet Bio Inc
Similar Industry Stocks (Biotechnology)
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin’s lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.